The editor's roundtable: bare-metal stents versus drug-eluting stents-indications and complications.

摘要

Dr. Friedewald has received honoraria from Novartis, East Hanover, New Jersey. Dr. Kastrati has received honoraria from Astra-Zeneca, Wilmington, Delaware; Bristol-Myers Squibb, Plainsboro, New Jersey; Cordis, Miami Lakes, Florida; and Eli Lilly, Indianapolis, Indianapolis. Dr. Roberts has received honoraria from Merck, Whitehouse Station, New Jersey; Schering Plough, Kenilworth, New Jersey; Pfizer, New York, New York; AstraZeneca; and Novartis. Dr. Vetrovec is a member of the speaker's bureaus of Pfizer; CV Therapeutics, Palo Alto, California; Eli Lilly; Cordis; and Stereotaxis, St. Louis, Missouri. Dr. Vetrovec has received education or research grants from Cordis; Eli Lilly; and The Medicines Company, Parsippany, New Jersey. Dr. Vetrovec has received end point committee contracts from Merck; Pfizer; Boston Scientific, Natick, Massachusetts; and Abbott Laboratories, Abbott Park, Illinois. Dr. Vetrovec has received consulting fees from Cordis and the United States Food and Drug Administration, Rockville, Maryland. Dr. Vetrovec owns stock in Merck; Pfizer; Medtronic, Minneapolis, Minnesota; Boston Scientific; and Johnson & Johnson, Piscataway, New Jersey. Dr. Windecker has received honoraria from Biotronik, Berlin, Germany; Boston Scientific; Biosensors, Victoria, Australia; Cordis; Medtronic; and Abbott Laboratories.